Azapirones versus placebo for panic disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Imai, Hissei ^a   Tajika, Aran ^a   Chen, Peiyao ^a   Pompoli, Alessandro ^b   Guaiana, Giuseppe ^c   Castellazzi, Mariasole ^b   Bighelli, Irene ^b   Girlanda, Francesca ^b   Barbui, Corrado ^b   Koesters, Markus ^d   Cipriani, Andrea ^e   Furukawa, Toshi A ^a  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^e WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; AZAPIRONE DERIVATIVE; BUSPIRONE; PLACEBO; UNCLASSIFIED DRUG;

AGORAPHOBIA; ALCOHOLISM; ANXIETY DISORDER; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HAMILTON DEPRESSION RATING SCALE; HUMAN; OUTCOME ASSESSMENT; PANIC; PREVALENCE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADULT; META ANALYSIS; PANIC DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGORAPHOBIA; ANTI-ANXIETY AGENTS; BUSPIRONE; HUMANS; PANIC DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929496374     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010828.pub2     Document Type: Review

References (83)

1. Pohl R, Balon R, Yeragani YK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989;22(Suppl 1):60-7.
2. Robinson D, Shrotriya RC, Alms DR, Messina M, Andary J. Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone. Psychopharmacology Bulletin 1989;25(1):21-6.
3. Sheehan D, Raj AB, Sheehan H, Soto S. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacology, Biochemistry, and Behavior 1988;29(4):815-7.
4. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder?. Journal of Clinical Psychopharmacology 1990;10(1):3-11.
5. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica 1993;88(1):1-11.
6. Bohm C, Robinson DS, Gammans RE, Shrotriya RC, Alms D, Leroy A, et al. Buspirone therapy in anxious elderly patients: a controlled clinical trial. Journal of Clinical Psychopharmacology 1990;10(3 Suppl):47S-51S.
7. Bohm C, Placchi M, Stallone F, Gammans RE, Alms DR, Shrotriya RC, et al. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. Journal of Clinical Psychopharmacology 1990;10(3 Suppl):38S-42S.
8. Bouvard M, Mollard E, Guerin J, Cottraux J. Study and course of the psychological profile in 77 patients experiencing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychotherapy and Psychosomatics 1997;66(1):27-32.
9. Broocks A, Bandelow B, Koch K, Bartmann KU, Kinkelbur J, Schweiger U, et al. Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacology 2002;27(2):270-8.
10. Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, et al.5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. European Neuropsychopharmacology 2003;13(3):153-64.
11. Bueno JR, Laks J. [Atividade ansiolitica da buspirona estudo comparativo com placebo e diazepam]. Journal Brasileiro de Psiquiatria 1988;37(2):97-9.
12. Cottraux J, Note ID, Cungi C, Légeron P, Heim F, Chneiweiss L, et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. British Journal of Psychiatry 1995;167(5):635-41.
13. Gershon S. Drug interactions in controlled clinical trials. Journal of Clinical Psychiatry 1982;43(12):95-8.
14. Goldberg HL. Buspirone - a new antianxiety agent not chemically related to any presently marketed drugs. Psychopharmacology Bulletin 1979;15(2):90-2.
15. Goldberg HL, Finnerty R. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. American Journal of Psychiatry 1979;136(9):1184-7.
16. Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. Journal of Clinical Psychiatry 1982;12(12 Pt 2):87-91.
17. Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM. Ipsapirone: evidence for efficacy in depression. Psychopharmacology Bulletin 1990;26(2):219-22.
18. Hongbo Z. A clinical comparative trial of buspirone in the treatment of anxiety neurosis. Chinese Journal of Nervous and Mental Disease 1994;20(5):277-9.
19. Hua H, Huaquing M. A comparative study in psychotherapy and drug in teatment of anxiety disorders. Chinese Journal of Nervous and Mental Disorder 1994;28(2):85-7.
20. Kai S, Mizuki Y, Kajimura N, Suetsugi M, Yamada M. Pharmaco-EEG studies on buspirone, a new anxiolytic drug, in high- and low-anxious humans. Clinical Neuropharmacology 1992;15(Suppl 1):5398.
21. Klaassen T, Riedel WJ, Van Praag HM, Menheere P, Griez E. Neuroendocrine response to meta-chlorophenylpiperazine and ipsapirone in relation to anxiety and aggression. Psychiatry Research 2002;113(1-2):29-40.
22. Lee ST, Park JH, Kim M. Eficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 2005;45(8):1004-11.
23. Lesch KP, Mayer S, Disselkamp-Tietze J, Hoh A, Schoellnhammer G, Schulte HM. Subsensitivity of the 5-hydroxytryptamine1A (5-HT1A) receptor-mediated hypothermic response to ipsapirone in unipolar depression. Life Science 1990;46(18):1271-7.
24. Lesch KP, Wiesmann M, Hoh A, Muller T, Disselkamp-Tietze J, Osterheider M, Schulte HM. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 1992;106:111-117.
25. Mavissakalian M, Michelson L. Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry 1986;47(3):117-22.
26. Miura S, Asai M, Ito K, Endo S, Ogura C, Kazamatsuri H, et al. Clinical study of buspirone on neurosis - a comparative double-blind trial with placebo. Clinical Evaluation 1992;19:447-75.
27. Murasaki M, Mori A, Endo S, Takemasa K, Hasegawa K, Kamijima K, et al. Late phase III. study of a new anxiolytic SM-3997 (tandospirone) on neurosis. Clinical Evaluation 1992;20:259-293.
28. Newton RE, Casten GP, Alms DR, Benes CO, Marunycz JD. The side effect profile of buspirone in comparison to active controls and placebo. journal of Clinical Psychiatry 1982;43(12 Pt 2):100-2.
29. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. Southern Medical Journal 1990;83(2):194-7.
30. Rakel R. Assessing the efficacy of antianxiety agents. The American Journal of Medicine 1987;82:1-6.
31. Rickels K. Recent advances in anxiolytic therapy. Journal of Clinical Psychiatry 1981;42(11):40-4.
32. Rickels K, DeMartinis N, Garcia-Espana F, Greenblatt DJ, Mandos LA, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. American Journal of Psychiatry 2000;157(12):1973-9.
33. Simeon J, Knott VJ, Dubois C, Wiggins D, Geraets I, Thatte S, et al. Buspirone therapy of mixed anxiety disorders in childhood and adolescence: a pilot study. Journal of Child and Adolescent Psychopharmacology 1994;4(3):159-70.
34. Tyrer P, Owen R. Anxiety in primary care: is short-term drug treatment appropriate?. Journal of Psychiatry Research 1984;18(1):73-8.
35. van Laar MW, Volkerts ER, Van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. Journal of Clinical Psychopharmacology 1992;12(2):86-95.
36. Zelvelder WG. Buspirone (Buspar), a double-blind comparative study of two dosing schedules [Buspirone (Busper); een dubbelblind vergelijkend onderzoek van twee doserings-schema's]. Journal for Drug Therapy and Research 1990;15(4):112-8.
37. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?. JAMA 2003;290(7):921-8.
38. Altman DG, Bland MJ. Detecting skewness for summary information. BMJ 1996;313(7066):1200.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Arlington, VA: American Psychiatric Publishing, 1994.
40. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder. American Psychiatric Association Practice Guideline for the Treatment of Panic Disorder. Arlington, VA: American Psychiatric Publishing, 2009.
41. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19(6):567-96.
42. Batelaan NM, Van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder: an update. International Journal of Neuropsychopharmacology 2011;15(3):403-15. [DOI: 10.1017/S1461145711000800]
43. Bhandari M, Busse JW, Jackowski D, Montori VM, Schünemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170(4):477-80.
44. Bijl RV, Ravelli A, Van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology 1998;33(12):587-95.
45. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [in French]. Therapie 1999;54(4):405-11.
46. Bruce SE, Vasile RG, Goisman RM, Salzman C, Spencer M, Machan JT, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. American Journal of Psychiatry 2003;160(8):1432-8.
47. Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Annals of Pharmacotherapy 2004;38(4):579-85.
48. Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha AABC, Kapczinski FFK, Silva de Lima M, et al. Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006115]
49. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
50. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa. 2000 October 25-28.
51. Diaz MR, Chappell AM, Christian DT, Anderson NJ, McCool BA. Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala. Neuropsychopharmacology 2011;36(5):1090-103.
52. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. American Journal of Psychiatry 1994;151(3):413-20.
53. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
54. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
55. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
56. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59(1):7-10.
57. Furukawa TA, Watanabe N, Churchil R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2]
58. Goisman RM, Warshaw MG, Steketee GS, Fierman EJ, Rogers MP, Goldenberg I, et al. DSM-IV and the disappearance of agoraphobia without a history of panic disorder: new data on a controversial diagnosis. American Journal of Psychiatry 1995;152(10):1438-43.
59. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry 2000;157(4):493-505.
60. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al. The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006;67(3):363-74.
61. Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Antidepressants versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010676]
62. Guaiana G, Barbui C, Chiodo D, Cipriani A, Davies SJC, Koesters M. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010677]
63. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. J.
64. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63(4):415-24.
65. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al. Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry 2008;192(5):362-7.
66. Kishi T, Meltzer Y, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. International Journal of Neuropsychopharmacology 2013;16(6):1259-66.
67. Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
68. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal 2003;326(7400):1167-70.
69. Moher D, Liberati A, TetzlaffJ, Altman DG, The PRISMA group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Medicine 2009;6(6):e1000097.
70. Napoliello MJ, Domantay AG. Buspirone: a worldwide update. British Journal of Psychiatry 1991;159(Suppl 12):40-4.
71. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. British Journal of Psychiatry 2008;193(3):229-34.
72. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. Journal of Neuroscience 2004;24(3):589-91.
73. National Institute for Health and Clinical Excellence. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults [CG113]. London: National Institute for Health and Clinical Excellence, 2011.
74. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proceedings of the National Academy of Sciences of the United States of America 1998;95(18):10734-9.
75. Payer D, Bolleau I, Guranda M, GraffA, Nakajima S, Meyer J, et al. Buspirone occupancy of D2/3 dopamine receptors in humans measured by positron emission tomography. Proceedings of the College on Problems of Drug Dependence, 75th Annual Scientific Meeting, San Diego, CA. 15-20 June 2013.
76. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O, Salanti G. Psychological therapies for panic disorder with or without agoraphobia in adults. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD011004;:]
77. Sheehan D, Raj AB, Sheehan H, Soto S. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacology, Biochemistry, and Behavior 1988;29(4):815-7.
78. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder?. Journal of Clinical Psychopharmacology 1990;10(1):3-11.
79. Starcevic V. Anxiety Disorders in Adults: A Clinical Guide. Oxford, UK: Oxford University Press, 2009.
80. Stein M, Steckler T, Lightfoot JD, Hay E, Goddard AW. Pharmacologic treatment of panic disorder. Current Topics in Behavioral Neurosciences 2010;2:469-85.
81. Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. American Journal of Psychiatry 2001;158(8):1326-8.
82. Wade AG. Antidepressants in panic disorder. International Clinical Psychopharmacology 1999;14(Suppl 2):13-7.
83. Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005335.pub2]